255 results about "DNA methylation" patented technology

The application provides a novel DNA methylation marker TAGMe-3 for tumor identification and use thereof. The TAGMe-3 gene sequence region has significant methylation difference between cancer tissues and paracancer tissues. As long as abnormal high methylation state of the TAGMe-3 gene sequence region is detected, the subject is determined to belong to a tumor high-risk population. Moreover, the significant difference of the TAGMe-3 presented between tumor tissues and non-tumor tissues exists in different types of tumors (Pan-cancer) in a wide range.

The invention belongs to the technical field of biological diagnosis, and particularly relates to application of a reagent for detecting DNA methylation of an RPL10 promoter region in preparation of a sow pregnancy diagnosis product. Through methylation high-throughput sequencing of blood DNA of pregnant sows and non-pregnant sows, it is found that the methylation level of a gene promoter region of the ribosomal protein L10 in the early pregnancy stage of the sows is remarkably reduced. The methylation level of the pregnant sow RPL10 is analyzed by using MSP, BSP and qMSP methods, and meanwhile, the ROC curve analysis result also shows that the RPL10 has diagnostic value. The results show that the method for detecting the RPL10 gene in the pig blood sample can be an effective method for diagnosing the early pregnancy of pigs. According to the invention, a pregnancy diagnosis technology based on RPL10 promoter region DNA methylation is preliminarily established, pig pregnancy detection methods are enriched, and a reference is provided for further exploring the DNA methylation level and the regulation mechanism of the pig pregnancy early stage.

The present invention discloses an in vitro method for obtaining DNA methylation biomarkers as exquisite DNA methylation positions in the human genome (i.e., CGIDs) that predict cervical cancer especially at as yet inaccessible early stages by examining progression of “categorical” DNA methylation alterations in three stages of premalignant lesions (cervical intraepithelial neoplasia (CIN)), progressing from CIN1 to CIN3. The present invention discloses combinations of CGIDs for detecting with high specificity and sensitivity cervical cancer by measuring their DNA methylation status and deriving a “methylation score”, which is useful as a biomarker for cervical cancer. Also disclosed are kits for predicting cervical cancer using such CGIDs using multiplexed next generation sequencing methylation assays, pyrosequencing assays and methylation specific PCR. The DNA methylation markers (CGIDs) described in the present invention are useful for cervical screening and early detection of cervical cancer by any person skilled in the art to detect cervical cancer.

The invention discloses a cancer profiling classification and prognosis prediction method based on generic cancer multi-omics data, and relates to a cancer profiling classification and prognosis prediction method. The invention aims to solve the problems of cancer subtype classification and prognosis prediction in generic cancer multi-omics. The method comprises the following steps: step 1, acquiring a multi-omics generic cancer data set, wherein the multi-omics generic cancer data set comprises a data set consisting of mRNA (messenger ribonucleic acid), DNA (deoxyribonucleic acid) methylation, miRNA (micro Ribonucleic Acid) and clinical prognosis data; 2, preprocessing the multi-omics cancer data set in the step 1; step 3, constructing a deep neural network model; 4, training the deep neural network model constructed in the step 3 based on the multi-omics generic cancer data set preprocessed in the step 2; and 5, carrying out cancer subtype classification and prognosis prediction on to-be-detected data based on the deep neural network model trained in the step 4. The invention belongs to the technical field of bioinformatics.

The invention discloses an application of leukocyte DNA methylation markers in colorectal tumor risk prediction, a series of leukocyte DNA methylation biomarkers related to colorectal tumors are researched, screened and verified, finally five methylation areas are obtained, a novel risk prediction model is constructed based on the five methylation areas, and the leukocyte DNA methylation markers have high clinical transformation potential and can be used for predicting the risk of colorectal tumors. And a novel risk stratification tool is provided for prevention and early screening of colorectal cancer.

The invention belongs to the technical field of gene detection, and particularly relates to a DNA methylation label-free fluorescence detection method, a reagent composition and application. The method comprises the following steps: cracking target DNA (Deoxyribose Nucleic Acid) by adopting GLaI endonuclease, and carrying out GLaI endonuclease reaction to obtain a digestion product; carrying out a double-cascade chain displacement amplification reaction on the obtained digestion product to obtain a double-cascade chain displacement amplification reaction product; carrying out CRISPR / Cas12a reaction on the obtained double-cascade chain displacement amplification reaction product, so as to obtain a CRISPR / Cas12a reaction product; in the CRISPR / Cas12a reaction, a G triplex is used as a signal source; and adding a fluorescent reaction reagent into the CRISPR / Cas12a reaction product, and measuring the fluorescence intensity of the CRISPR / Cas12a reaction product to obtain a methylation detection result of the target DNA. The detection method has the characteristics of low cost, universality, high sensitivity, high accuracy, good selectivity and the like.

The invention discloses a reagent combination for protecting fragment integrity in DNA methylation detection, the reagent combination is used for protecting fragment integrity in DNA methylation detection sample transformation, and the reagent combination comprises tetrahydrofurfuryl alcohol, L-ascorbyl palmitate and ethylenediamine tetraacetic acid; wherein the volume concentration of the tetrahydrofurfuryl alcohol is 10%-80%; the molar concentration of the L-ascorbyl palmitate is 10 mM to 100 mM; the molar concentration of the ethylenediamine tetraacetic acid is 1 mM to 10 mM. The invention also provides a kit and a method for DNA conversion by using the kit. According to the reagent combination, damage of sulfite to DNA in the transformation process can be reduced, DNA degradation is prevented, a transformed fragment is longer than that of a traditional transformation method, the DNA recovery concentration and the library concentration are higher, follow-up detection is facilitated, and the sensitivity of a follow-up detection method is improved.

The present invention discloses a nucleic acid composition, a kit and a detection method for detecting methylation of liver cancer-related genes. The nucleic acid composition is a first nucleic acid composition, a second nucleic acid composition or a combination of the first nucleic acid composition and the second nucleic acid composition. The first nucleic acid composition comprises: a methylation-specific primer and a probe for a target site of the EMX1 gene, a methylation-specific primer and a probe for a target site of the OTX2 gene, and a methylation-specific primer and probe for a target site of the DAB2IP gene. The second nucleic acid composition comprises: a methylation-specific primer and a probe for a target site of the Septin9 gene, a methylation-specific primer and a probe for a target site of the CDKL2 gene, and a methylation-specific primer and probe for a target site of the GSTP1 gene. The kit configured with the nucleic acid composition discovered in the present invention determines whether a test sample has become cancerous based on the degree of DNA methylation of the test sample, thereby providing a clinically simple and accurate liver cancer screening method, which has a very positive significance for the detection of liver cancer.

This invention discloses a method for constructing a gene methylation diagnostic model for differentiated thyroid cancer (PTC). The method includes the following steps: S1, obtaining a test sample; S2, extracting and storing DNA from the test sample; S3, performing methylation analysis; S4, establishing a diagnostic model based on DNA methylation, where the model shows that patients with cg03596178, cg06033721, cg06688989, cg07209244, cg07485775, cg14484681, cg19979108, and cg20943461 are more likely to experience disease progression and are considered risk factors; S5, cross-validating and evaluating the performance to obtain the gene methylation diagnostic model. This model, by detecting and statistically analyzing specific methylation sites, can differentiate patients with recurrent or metastatic characteristics in differentiated thyroid cancer. The relevant model can assist in the clinical diagnosis and follow-up of thyroid patients.

The invention discloses a gene marker for diagnosing latent tuberculosis infection and application of the gene marker, and belongs to the technical field of biological medicine. According to the present invention, the latent tuberculosis infection early diagnosis marker is screened based on the peripheral blood whole genome DNA methylation map, the new target is provided for the diagnosis of latent tuberculosis infection, the diagnosis efficiency of the marker is evaluated through pyrosequencing, the corresponding detection kit and the use method are developed, and the rapid and accurate diagnosis of latent tuberculosis infection is achieved.

The present disclosure generally relates to methods and compositions for interrogating and / or analyzing DNA methylation in a biological sample. In some aspects, the present disclosure relates to methods for determining the methylation status of a region of interest of genomic DNA. In some aspects, the methylation status is analyzed by interrogating converted DNA in which the sequence of the converted DNA is indicative of the methylation state of the DNA. In some aspects, the methods comprise generating a collective signal that is based on the methylation states of a plurality of sequences or residues in the DNA, and that is representative of the methylation status of the region of interest as a whole.

The invention discloses a gene level DNA methylation, transcriptome and proteome conjoint analysis method based on a snkemake framework, which comprises the following steps: preprocessing original data of DNA methylation and / or transcriptome and / or proteome, analyzing gene methylation, analyzing transcriptome and / or proteome, and analyzing the transcriptome and proteome. Based on gene methylation analysis data, the preprocessed transcriptome data and the preprocessed proteome data, correlation analysis and / or difference intersection analysis and / or enrichment pathway conjoint analysis are / is carried out, finally analysis results are sorted, and a visual report is generated. The method has comprehensive results, and relates to quantification, difference analysis and pathway enrichment analysis of gene methylation, and correlation analysis, difference intersection analysis and enrichment pathway joint analysis of integrated DNA methylation and / or transcriptome and / or proteome data; automatic arrangement, verification, visualization and report generation of analysis results are realized; all operation steps can be traced, and corresponding analysis log records are generated. The invention further discloses a related system and application.

The invention discloses an integrated micro-fluidic chip which comprises a chip main body consisting of a reaction layer, a channel layer and a detection layer which are sequentially sealed from top to bottom in the vertical direction, the chip main body internally comprises a first fluid channel network and a second fluid channel network; the first fluid channel network comprises a first reaction chamber, a first mixing unit, a first transfer sample injection unit, a first digital detection unit and a fluid channel for connecting the structural units, which are communicated in sequence; the first fluid channel network and the second fluid channel network have the same structure and size, and the first fluid channel network and the second fluid channel network are arranged in a mirror symmetry mode along the central symmetry axis of the chip body. According to the chip disclosed by the invention, methylation sensitive incision enzyme digestion treatment, reagent mixing and digital amplification detection can be integrated on a closed micro-fluidic platform, and'sample input-result output 'is realized for the first time aiming at DNA methylation quantitative detection.

The invention relates to a tumor-related DNA methylation marker combination, which is selected from at least one of the following: a target sequence as shown in SEQ ID NO: 1-SEQ ID NO: 10, a nucleic acid fragment with the length of at least 15 oligonucleotides or a complementary nucleic acid fragment thereof, and the nucleic acid fragment comprises at least one methylation site indicated by CG. The invention also relates to a detection kit for the methylation marker combination. According to the invention, the combination of the co-methylation states of a plurality of specific methylation regions is used for distinguishing and analyzing the occurrence of tumors, especially kidney cancer, the specific methylation combination has high sensitivity for distinguishing the occurrence of kidney cancer, and the detection method is simple, convenient and feasible. The primer pair combination of the kit overcomes the defect of false positive caused by detection mismatch of a single methylation site in the aspect of primer sequence design, and the interaction between a plurality of methylation biomarker primers and probe pair combinations is considered.

The invention discloses heat-resistant saccharomyces cerevisiae of a heterozygous human DNA methylation system as well as a construction method and application of the heat-resistant saccharomyces cerevisiae. The construction method comprises the following steps: determining a to-be-knocked-in saccharomyces cerevisiae target gene locus CAN1, and carrying out annular PCR amplification by taking a target sgRNA sequence as a homologous arm and an original gRNA plasmid as a template to obtain a gRNA plasmid; constructing a to-be-knocked-in gene segment, and transferring the constructed gRNA plasmid, the segment 1 and the segment 2 into BY4741-Cas9 saccharomycetes through a saccharomyces cerevisiae lithium acetate conversion method; the CRISPR plasmid is lost by adopting an iteration method to obtain a saccharomyces cerevisiae strain which is integrated into a genome and has DNA methylation modification, and the saccharomyces cerevisiae strain is named as yHL006. The invention constructs a saccharomyces cerevisiae chassis strain capable of stably expressing a DNA methylation system. Any auxotrophic selection marker is not occupied, and the complete amino acid synthesis capability and corresponding gene loci of the yeast are completely reserved. The heat stress resistance phenotype of the DNA methylation strain is verified, and the heat resistance of the yeast can be improved by the introduced DNA methylation system.

The present invention relates to a method of evaluating the effect of at least one test component of an animal feed on at least the performance and / or the overall health of a test animal consuming an animal feed having the test component, the method comprising the steps of: (a) determining a test methylation profile of one or more preselected methylation sites within the DNA of the test animal; (b) comparing the test methylation profile from (a) to at least one control methylation profile from a control animal consuming animal feed free of the test component belonging to the same biologic classification unit as the test animal; and wherein the results of (a) are used to determine the performance and / or overall health of the test animal; and (c) comparing the test methylation profile from (a) to (i) a first reference methylation profile from a control animal having good performance and / or overall health belonging to the same biologic classification unit as the test animal; and / or (ii) a second reference methylation profile derived from a control animal having poor performance and / or overall health, belonging to the same bioclassification unit as the test animal; and wherein a significant similarity of the test methylation profile of (a) compared to the control methylation profile indicates that the test component has no effect on the performance and / or overall health of the test animal; and wherein a significant difference in the test methylation profile of (a) compared to the control methylation profile indicates that the test component has an effect on the performance and / or overall health of the test animal; and wherein a significant similarity of the test methylation profile of (a) to the first reference methylation profile and / or a difference of the test methylation profile of (a) to the second reference methylation profile indicates that the test animal has good performance and / or overall health as a control cell; and / or wherein the difference in the test methylation profile of (a) compared to the first reference methylation profile and / or the significant similarity of the test methylation profile of (a) to the second reference methylation profile indicates that the test animal has poor performance and / or overall health as a control animal; and wherein the test animal is selected from livestock or poultry.

The present invention belongs to the field of molecular biology and genetics, and in particular relates to a method for editing a bovine gene based on Pro-iCHI. The present invention provides a method for editing a bovine gene based on Pro-iCHI. Protamine is transiently expressed in gene-edited b-haSCs, which are then injected to mature oocytes to obtain reconstructed embryos. Protamine can eliminate abnormal DNA methylation resulting from oocyte intracytoplasmic haSCs injection and enable the nucli to compress into sperm-like structures, and the obtained bovine Pro-iCHI embryos can successfully develop into blastocysts, with a blastocyst rate comparable to that of the embryos obtained by in vitro fertilization. Moreover, in the present invention, a protamine-encoding gene is inserted into a Saccharomyces cerevisiae protein expression vector for transient expression, which ensures that abnormal DNA methylation is erased, without integration into the genome resulting in the insertion of exogenous genes.

The application discloses a kind of based on DNA methylation's construction method of biological age prediction model, the application is downloaded from GEO data website, derived from Chinese population, contains calendar age data, whole blood sample 450k methylation chip data, by the method of elastic network combined bootstrap, 31 methylation sites of modeling candidate are screened, multiple linear regression, support vector machine, random forest and gradient boosting regression tree are used to carry out preliminary construction and evaluation of model, then further filter methylation sites using full subset regression, obtain methylation age prediction model based on 18 methylation sites.Finally, using any provincial team natural population data, methylation age prediction model is optimized, and finally the biological age prediction model based on 18 methylation sites is obtained.The model is suitable for Chinese population, the number of methylation sites contained is less, is not affected by blood cell components, and the prediction accuracy is good.

The utility model relates to the technical field of test devices, and discloses an oscillation device for a DNA methylation test, which comprises an oscillation shell and a test tube, an oscillation seat is arranged on the inner side of the oscillation shell, positioning grooves are uniformly formed in the upper surface of the oscillation seat, and the lower end of the test tube is movably connected with the positioning grooves. A driving motor is controlled to work, a first cam can be driven to rotate through a first connecting rod, so that a vibration plate and a vibration seat are driven to vibrate, a test tube on the inner side of a positioning groove is further driven to vibrate up and down, and a second cam can be driven to rotate in a shell through combination of a first bevel gear, a second connecting rod and a second bevel gear; through combination of a connecting block, a first guide rod and a first spring, a vibration block can be driven to move leftwards and rightwards, through combination of a second sliding block, a second sliding groove and a second spring, when the vibration block moves rightwards, a vibration seat can be knocked, so that a test tube on the inner side of a positioning groove is driven to vibrate leftwards and rightwards, and the vibration effect of the test tube is further improved.

The invention provides a marker for evaluating biological age, a probe composition and application thereof. The marker is an SCGN gene and / or a TRIM59 gene. According to the present invention, with the application of the marker, the methylation state of the genes can be sensitively and specifically detected, and the marker is used for constructing the age prediction model based on DNA methylation so as to detect the biological age.

The present disclosure includes, among other things, methods, kits, and systems for determining a status of lung cancer. In various embodiments, the present disclosure relates to the use of one or more histone modifications, chromatin accessibility, binding of one or more transcription factors, and / or DNA methylation as features of a status of lung cancer. In some embodiments, differential modifications and / or differential accessibility are detected and quantified at one or more genomic loci in a biological sample, e.g., cell-free DNA (cfDNA), from a liquid biopsy sample obtained or derived from a subject having lung cancer. In various embodiments, the determined status can be used, e.g., to select a treatment for lung cancer and / or to treat lung cancer.

The invention discloses a mental disease typing method and system integrating DNA methylation and neuroimaging, and the method is a neuroimaging biological annotation method integrating DNA methylation and brain connection group data, and comprises the steps: recognizing brain network features related to a specific molecular phenotype in a whole brain range through a machine learning model; and mechanism-sensitive layering of the mental disorder heterogeneity group is realized. The method does not need to depend on a prior classification or hypothesis mechanism, can be suitable for different types of mental disorder people, provides technical support for exploring potential biological mechanisms and identifying targeted therapy groups, and has high generalizability and clinical application prospects.

The invention discloses a primer composition for integrated detection of an SNP (Single Nucleotide Polymorphism) genetic marker and a DNA (Deoxyribose Nucleic Acid) methylation molecular marker and application of the primer composition. The primer composition provided by the invention is composed of 142 kinds of primers; the nucleotide sequences of the 142 primers are sequentially as shown in SEQ ID NO: 1 to SEQ ID NO: 142. According to the primer composition, multiple PCR amplification is carried out in the same system, high-throughput sequencing is carried out after PCR amplification products are subjected to library building, and integrated detection of 55 SNP and 11 DNA methylation molecular markers of the same sample can be achieved at a time. By adopting the integrated detection system provided by the invention, the peripheral blood, vaginal secretion and seminal fluid of people can be identified, and the age of a peripheral blood sample donor can be deduced. According to the invention, a good technical basis is provided for obtaining diversified biological information of on-site detected materials in forensic medicine research and practice.

The invention provides oligonucleotide targeting DNMT1, a composition or a vector containing the oligonucleotide, a method for regulating DNMT1 expression by using the oligonucleotide, and a method for screening a target gene regulated by DNA methylation. The invention also provides a compound targeting the LIFR, a composition or a vector containing the compound and a method for regulating the expression of the LIFR by using the compound.

The present application provides tools for rapidly, accurately, and accessibly quantifying endonuclease activity. The system is broadly capable of qualifying enzymatic reagents, detecting chemical inhibitors, and optimizing reaction conditions. Minimal adaptations could further enable use in high-throughput screens for enhancers or inhibitors of specific endonucleases. In this context, the present invention demonstrates the utility of mitochondrial DNA (mtDNA) - which is abundant in plasma as cell-free DNA ("cfDNA") and naturally has minimal methylation - as an endogenous digestion control system in MSRE-dependent methylation assays. While demonstrated in the context of qPCR, the control endogenous digestion control systems of the present invention are broadly applicable to MSRE-dependent methylation assays generally, and particularly to those assays that use a multiplex of MSREs having different recognition sequences.

The present disclosure includes, among other things, methods, kits, and systems for determining the status of MS in a subject. In various embodiments, the present disclosure relates to the use of one or more histone modifications, chromatin accessibility, binding of one or more transcription factors, and / or DNA methylation that are characteristic of the status of MS. In some embodiments, differential modifications and / or differential accessibility are detected and quantified, at one or more genomic loci of a biological sample, e.g., in cell-free DNA (cfDNA) from a liquid biopsy sample obtained or derived from a subject with MS. In various embodiments a determined status is useful, e.g., in selecting treatment for and / or treating MS.

This invention relates to a method and system for screening osteoarthritis biomarkers based on Trans-CNN feature fusion, and relates to the field of medical technology. It addresses the problem that in existing osteoarthritis biomarker screening research, traditional Transformer models excel at capturing global relationships of features in input text sequences, while traditional CNN models focus more on local feature relationships. The fusion of these two approaches can reduce the accuracy of osteoarthritis diagnosis. The proposed Trans-CNN feature fusion model cleverly combines the global context awareness capability of Transformer with the local feature extraction advantage of CNN through a dynamic gating mechanism. This enables a more comprehensive capture of the complex regulatory relationships in DNA methylation data, thus facilitating the screening of osteoarthritis biomarkers.

The present invention relates to DNA methylation markers for diagnosing esophageal cancer and gastric cancer and uses thereof, more particularly to a combination of DNA methylation markers capable of determining the presence or absence of esophageal cancer and gastric cancer and uses thereof. The DNA methylation markers for diagnosing esophageal cancer and gastric cancer according to the present invention can diagnose esophageal cancer and gastric cancer with high accuracy using only DNA methylation information from blood samples without using esophageal cancer and gastric cancer tissue samples, and can therefore be useful for the early diagnosis of esophageal cancer and gastric cancer.

The invention provides a multi-omics integrated marker for early screening of colorectal cancer, which comprises an lncRNA marker combination, a protein marker combination, an mRNA marker combination, a metabolism marker combination and a methylation marker combination, and relates to the technical field of gene detection and medical treatment. According to the invention, 11 groups of colorectal cancer tissues and para-carcinoma tissues paired with the colorectal cancer tissues are subjected to transcriptome, proteome and metabolome sequencing, and 61 cases of colorectal cancer tissues and 24 cases of para-carcinoma tissues are subjected to simplified methylation sequencing; by integrating and analyzing the multi-omics data, a multi-level interaction network is obtained, and the network contains lncRNA, protein, mRNA, metabolites and DNA methylation markers which have a close interaction relationship, and has a wide application prospect in diagnosis and treatment of colorectal cancer.

The present disclosure relates to a DNA methylation markers combination for bladder cancer risk stratification, which includes methylation regions as denoted by any one or more of SEQ ID NOS:1-22 or any one or more of complementary sequences thereof. The present disclosure further provides a clinical application of the three-class stratification mode before operation based on the selected appropriate molecular marker combinations, to promote the rational use of current diagnosis and treatment methods, consequently patients with negative BC can avoid excessive invasive cystoscopy, while HR-NMIBC or MIBC can expedite diagnosis and surgical operations, and the definite LMR-NMIBC patients can follow standard diagnostic modalities.